Ganoderma lucidum transcription factor C2H2-3, method for synthesizing ganoderic acid by using same and application of ganoderma lucidum transcription factor C2H2-3

The regulating SQS gene expression by the Ganoderma lucidum transcription factor C2H2-3 has solved the problem of low Ganoderma lucidum acid content, achieved the effect of improving Ganoderma lucidum synthesis, and provided a technical basis for cultivating Ganoderma lucidum varieties with high yield Ganoderma lucidum acid.

CN119061026AInactive Publication Date: 2024-12-03ZHEJIANG SHOUXIANGU PHARMA CO LTD +2
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411326456.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Ganoderma lucidum acid has a low content in Ganoderma lucidum, and the existing technology is difficult to effectively analyze its biosynthesis pathways and regulatory mechanisms, which limits the development of Ganoderma lucidum varieties with high yield Ganoderma lucidum acid.

Method used

By studying the interaction mechanism of the Ganoderma lucidum transcription factor C2H2-3 and the SQS gene, a recombinant vector is constructed to bind to the SQS gene promoter and positively regulate SQS gene expression, thereby increasing the synthesis content of Ganoderma lucidum acid.

Benefits of technology

Ganoderma lucidum transcription factor C2H2-3 can effectively regulate SQS gene expression and increase the content of Ganoderma lucidum acid, providing the basis for cultivating new high-quality Ganoderma lucidum varieties.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061026A_ABST
    Figure CN119061026A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of molecular biology and genetic engineering, and particularly relates to a ganoderma lucidum transcription factor C2H2-3, a method for synthesizing ganoderic acid by using the ganoderma lucidum transcription factor C2H2-3 and application of the ganoderma lucidum transcription factor C2H2-3. The invention provides a ganoderma lucidum transcription factor C2H2-3 (an amino acid sequence is shown as SEQ ID NO.2) with a nucleotide sequence shown as SEQ ID NO.1, and further provides application of the transcription factor C2H2-3 in activation of SQS gene expression of ganoderma lucidum. The ganoderma lucidum transcription factor C2H2-3 provided by the invention is combined with a ganoderma lucidum SQS gene promoter and positively regulates and controls the expression of an SQS gene; key enzymes participating in ganoderic acid anabolism can be regulated and controlled, so that the content of ganoderic acid in lucid ganoderma is regulated and controlled.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of molecular biology and gene engineering, and specifically relates to a ganoderma transcription factor C2H2-3 and a method and application thereof for synthesizing ganoderma acid. Background Art

[0002] Ganoderma Lucidum is a traditional large fungus with medicinal and edible properties, which has the effects of replenishing qi and calming the mind, relieving cough and relieving asthma. Ganoderma contains a variety of bioactive ingredients, with extremely high nutritional and health value and economic development prospects. Triterpenes are the main bioactive secondary metabolites in Ganoderma, among which Ganoderma triterpenoid acids, referred to as Ganoderic acids (GAs), are the core components of Ganoderma's medicinal effects. Studies have shown that Ganoderic acids play an important role in tumor treatment, anti-oxidation, inhibition of cholesterol synthesis, inhibition of angiotensin converting enzyme activity, inhibition of histamine release, and anti-HIV. However, the main way to obtain Ganoderic acid is to extract it from Ganoderma fruiting bodies and spores, and the content of Ganoderic acid in Ganoderma is relatively low. Therefore, analyzing the biosynthetic pathway of Ganoderic acid and its regulatory mechanism is of great significance for cultivating Ganoderma varieties with high Ganoderic acid production.

[0003] Ganoderic acid is synthesized through the mevalonate pathway (MVA) with acetyl-CoA as the precursor. In the MVA pathway, there are two important branches for the synthesis of ganoderic acid, one branch is from farnesyl pyrophosphate to geranyl pyrophosphate, and the other branch is from farnesyl pyrophosphate to lanosterol. The key genes that have been cloned and reported in these two branches are FPS, MVD, AACT, LS, HMGR, HMGS, IDI, SQS and OSC genes, which directly regulate the synthesis of ganoderic acid and are the key to the synthesis and accumulation of ganoderic acid. Among them, squalene synthase (SQS) is the first key enzyme that catalyzes the transition of the MVA pathway to triterpene biosynthesis, and is also a key enzyme involved in the anabolism of ganoderic acid. Squalene synthase (SQS) can catalyze the carbon flow in the isoprene pathway to triterpene biosynthesis. The activity of SQS is related to the production of triterpene compounds such as squalene, and is a key enzyme in the synthesis of triterpene compounds such as squalene. In recent years, studies have been conducted on cloning and constructing vectors of SQS genes in different plants such as ginseng, rice, and Paris polyphylla, exploring the mechanism of triterpenoid synthesis in plants at the molecular level and exploring the optimal conditions for gene expression through gene transformation.

[0004] Based on the above background, this patent studies the interaction mechanism between the SQS gene of Ganoderma lucidum and the transcription factor C2H2-3, providing a certain basis for the regulatory mechanism of ganoderic acid, and is also of great significance for the cultivation of high-quality new varieties of Ganoderma lucidum. Summary of the invention

[0005] In order to solve the above problems, the present invention provides a transcription factor C2H2-3 and its application in activating SQS gene expression.

[0006] In one aspect, the present invention provides a Ganoderma lucidum transcription factor C2H2-3, the nucleotide sequence of the Ganoderma lucidum transcription factor C2H2-3 is shown in SEQ ID NO.1.

[0007] Specifically, the nucleotide sequence may be a sequence optimized for codon degeneracy, and may be used to encode the aforementioned Ganoderma transcription factor C2H2-3.

[0008] Specifically, the Ganoderma lucidum transcription factor C2H2-3 positively regulates the expression of Ganoderma lucidum SQS by binding to the Ganoderma lucidum SQS gene promoter.

[0009] In yet another aspect, the present invention provides a recombinant vector, wherein the recombinant vector comprises the aforementioned Ganoderma lucidum transcription factor C2H2-3.

[0010] Specifically, the type of the recombinant vector is plasmid, phage or virus.

[0011] More specifically, the type of the recombinant vector is a plasmid.

[0012] Preferably, the plasmid is pGADT7-AD or pGreenII 62-SK.

[0013] Further preferably, when the plasmid is pGADT7-AD, the primers for amplifying the Ganoderma lucidum transcription factor C2H2-3 are shown in SEQ ID NO.4-5;

[0014] When the plasmid is pGreenII 62-SK, the primers for amplifying the Ganoderma lucidum transcription factor C2H2-3 are shown in SEQ ID NO.6-7.

[0015] In another aspect, the present invention provides a cell comprising the aforementioned Ganoderma transcription factor C2H2-3 or the recombinant vector.

[0016] Specifically, the cell is a microbial cell, a plant cell or an animal cell.

[0017] More specifically, the cells are microbial cells.

[0018] Preferably, the microbial cells include, but are not limited to, Escherichia coli, yeast, Agrobacterium or Bacillus subtilis.

[0019] Further preferably, the microbial cell may be yeast or Agrobacterium.

[0020] In another aspect, the present invention provides a method for synthesizing ganoderic acid, wherein the method is biosynthesized through the aforementioned ganoderic transcription factor C2H2-3 or recombinant vector or cell.

[0021] In yet another aspect, the present invention provides the use of the aforementioned Ganoderma transcription factor C2H2-3 or recombinant vector or cell or method in the synthesis of ganoderic acid.

[0022] The technical effects achieved by the present invention are:

[0023] (1) The Ganoderma lucidum transcription factor C2H2-3 binds to the Ganoderma lucidum SQS gene promoter and positively regulates the expression of SQS.

[0024] (2) The Ganoderma lucidum transcription factor C2H2-3 can regulate the key enzyme genes involved in the synthesis and metabolism of ganoderic acid, thereby increasing the content of ganoderic acid in Ganoderma lucidum. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 This is the heat map of C2H2-3 gene expression.

[0026] Figure 2 This is the map of the recombinant vector pGADT7-C2H2-3.

[0027] Figure 3 This is the map of the recombinant vector pGreenII 62SK-C2H2-3.

[0028] Figure 4 Analyze the results for yeast one-hybrid assay.

[0029] Figure 5 These are the results of dual luciferase reporter experiment analysis, where A is the result of dual luciferase reporter experiment; B is the result of fluorescence imaging. DETAILED DESCRIPTION

[0030] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0031] The C2H2-3 and SQS in the present invention are both derived from Ganoderma lucidum.

[0032] Example 1

[0033] Yeast one-hybrid assay

[0034] To identify whether C2H2-3 can directly regulate SQS genes, we first conducted a yeast one-hybrid assay to verify:

[0035] 1. Construction of recombinant vector

[0036] Using the gDNA of Ganoderma lucidum variety Xianzhi No. 2 as a template, the promoter region of 2000 bp before the start codon ATG of the SQS gene was cloned (the nucleotide sequence is shown in SEQ ID NO.3), the primer sequences of the SQS gene promoter region were amplified as shown in SEQ ID NO.8-9, and constructed into the pAbAi vector (manufacturer: Shanghai Zeye Biological Co., Ltd.; product number: ZY8159; insertion site: HindIII, XmaI) to obtain the recombinant vector pAbAi-SQS.

[0037] SEQ ID NO.3:

[0038]

[0039] SEQ ID NO.8(F): 5ˊ-TAGGGTCTGCTCGATTTTCG-3ˊ;

[0040] SEQ ID NO.9(R): 5ˊ-TATGACGAAAGAGTTGGTAG-3ˊ.

[0041] Using the cDNA of the Ganoderma lucidum variety Xianzhi No. 2 as a template, the full-length coding region of the C2H2-3 gene was cloned (the CDS sequence of C2H2-3 is shown in SEQ ID NO.1, and the corresponding amino acid sequence is shown in SEQ ID NO.2), and the homologous recombination primer sequences used to amplify the CDS region of C2H2-3 are shown in SEQ ID NO.4 and SEQ ID NO.5, respectively. The construct was constructed into the pGADT7-AD vector to obtain the recombinant vector pGADT7-C2H2-3.

[0042] SEQ ID NO.1:

[0043]

[0044] SEQ ID NO.2:

[0045] MADTENVTVPFFKKKSRGRPVTSRKRSASPPATAMTVPVASSSKSQVVLPSRKATANLLSAGTKRTVSQRQDDDDGEDTREGPDVKWTAAGSHVNAALEILQGDEAEELLAKRRRSEKKDEDEEDAPDDGLYRGQKAYKAHIRKNQEVPKAMRVGPQRSNNSTIRTV TIVDYQPDVCKDYKETGYCGYGDSCKFLHDRGTYLQGWQLDKLAADPKKQAGEDASDTDSDDEDIPFACLICRKPYTDPVVTRCEHYFCSACAIKRFAKTPKCAACGTPTGGIFNRADKVIAKLKKKQEAADEDGAGEDGDGKGPAGGVQIEGLGKASGSEDEDED.

[0046] SEQ ID NO.4(F):

[0047] GCCATGGAGGCCAGTGAATTCATGGCCGATACTGAGAACG;

[0048] SEQ ID NO.5(R):

[0049] CAGCTCGAGCTCGATGGATCCGTCTTCGTCCTCGTCCTCG.

[0050] 2. The recombinant vector pAbAi-SQS constructed on pAbAi and the pGADT7-AD empty vector were co-transformed into the yeast competent cell Y2H (manufacturer: Shanghai Jingkang Bioengineering Co., Ltd.; catalog number: JK-G8044) as the control group, and co-transformed with the pGADT7-AD recombinant vector as the experimental group, and applied to SD / -ura / -leu defective medium and cultured at 30℃ for 3-4 days. Pick more than 10 positive clones and culture them in SD / -ura / -leu liquid culture medium at 30℃ shaking incubator until OD 600>1.5, centrifuge at 1000rpm for 2min, discard the supernatant, resuspend with sterile water to OD 600≈0.2, and culture at 30℃ for 2-3 days on SD / -ura / -leu solid medium containing AbA (Aureo basidin A) at the original, 1 / 10, 1 / 100, and 1 / 1000 times. The results showed that on SD / -ura / -leu defective medium, by adding 100ng / mL AbA to inhibit the self-activation of the promoter, it was found that the growth ability of the combination of C2H2-3 and SQS co-transfection was significantly better than that of the control ( Figure 4 ), indicating that C2H2-3 can directly bind to the SQS promoter in yeast cells.

[0051] Example 2

[0052] Dual luciferase reporter assay

[0053] The dual luciferase system was used to analyze the transcriptional activity of the SQS gene by C2H2-3 protein in tobacco to verify the transcriptional activity. The pGreenII-62sk-C2H2-3 and pGreenII-0800-SQS (pGreenII-0800 manufacturer: Shanghai Zeye Biotechnology Co., Ltd.; product number: ZY6124; insertion site: HindIII, XmaI) promoter recombinant vectors were constructed (the homologous recombination primer sequences used to amplify the C2H2-3 CDS region are shown in SEQ ID NO.6 and SEQ ID NO.7, respectively), and transformed into GV3101-pSoup-P19 (manufacturer: Shanghai Weidi Biotechnology Co., Ltd.; product number: AC1003M) Agrobacterium tumefaciens competent cells. Before use, Agrobacterium (pGreenII-62sk-C2H2-3 and pGreenII-0800-SQS promoter bacterial solution) stored at -80°C was streaked on LB + 50 μg / mL kanamycin (kanamycin, Kan) + 25 μg / mL rifampicin (rif) solid medium for activation, and then a single clone was picked out and inoculated into 0.6 mL and then inoculated into 5 mL and 20 mL of the above liquid medium in a ratio of 1:100 overnight until the OD value of the stable phase was 0.6 mL. 600 >2.0, centrifuge at 5000rpm for 10min at room temperature, collect bacterial precipitate, resuspend with 1×MMA solution and mix bacterial solution until the final transcription factor and promoter OD600=0.5, place in dark place at room temperature for 3h and then inject into Nicotiana benthamiana. Select 4-5 week old healthy Nicotiana benthamiana and keep it in dark place for 24h. Place it in dark place for 1-2d after injection, then light cycle 14 / 10h for 3-4d, then select 0.5cm 2Add 500μL of Glo lysis solution (manufacturer: Beijing Zhaosheng Lab Trading Co., Ltd.; item number: 0000566337) to the injection area and grind. After full lysis, centrifuge at 12000rpm and 4℃ for 3min, take 50μL of supernatant + 50μL of luciferin reaction substrate and react at room temperature for 10min, use a microplate reader to measure luciferase fluorescence A, then add 50μL of stop solution and react for 10min and then measure its Renilla fluorescence B, and calculate whether there is an interaction between the transcription factor and the promoter by the A / B ratio. The results of the dual luciferase reporter experiment show ( Figure 5 ), C2H2-3 can activate the promoter of SQS.

[0054] SEQ ID NO.6(F):

[0055] CGCTCTAGAACTAGTGGATCCATGGCCGATACTGAGAACG;

[0056] SEQ ID NO.7(R):

[0057] TTCAGCGTACCGAATTGGTACCTCAGTCTTCGTCCTCGTCC.

[0058] It should be understood that the various forms of processes shown above can be used to reorder, add or delete steps. For example, the steps described in the disclosure of the present invention can be performed in parallel, sequentially or in different orders, as long as the desired results of the technical solution disclosed in the present invention can be achieved, and this document does not limit this.

[0059] The above specific implementations do not constitute a limitation on the protection scope of the present invention. It should be understood by those skilled in the art that various modifications, combinations, sub-combinations and substitutions can be made according to design requirements and other factors. Any modification, equivalent substitution and improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A Ganoderma lucidum transcription factor C2H2-3, characterized in that: The nucleotide sequence of the Ganoderma lucidum transcription factor C2H2-3 is shown in SEQ ID NO.

1.

2. A recombinant vector, characterized in that: The recombinant vector comprises the Ganoderma lucidum transcription factor C2H2-3 described in claim 1.

3. The recombinant vector according to claim 2, characterized in that The type of the recombinant vector is plasmid, phage or virus, preferably plasmid.

4. The recombinant vector according to claim 3, characterized in that The plasmid is pGADT7-AD or pGreenII62-SK.

5. The recombinant vector according to any one of claims 3 to 4, characterized in that When the plasmid is pGADT7-AD, the primers for amplifying the Ganoderma lucidum transcription factor C2H2-3 are shown in SEQ ID NOs.4-5; when the plasmid is pGreenII 62-SK, the primers for amplifying the Ganoderma lucidum transcription factor C2H2-3 are shown in SEQ ID NOs.6-7.

6. A cell comprising the Ganoderma lucidum transcription factor C2H2-3 according to claim 1 or the recombinant vector according to any one of claims 2 to 5.

7. The cell according to claim 6, characterized in that The cells are microbial cells, plant cells or animal cells.

8. The cell according to claim 7, characterized in that The cells are microbial cells, preferably yeast or Agrobacterium.

9. A method for synthesizing ganoderic acid, characterized in that: The method is carried out biosynthesis through the Ganoderma transcription factor C2H2-3 described in claim 1 or the recombinant vector described in any one of claims 2-5 or the cell described in any one of claims 6-8.

10. Use of the Ganoderma transcription factor C2H2-3 according to claim 1, the recombinant vector according to any one of claims 2 to 5, the cell according to any one of claims 6 to 8, or the method according to claim 9 in synthesizing ganoderic acid.

Citation Information

Cited By

  • Ganoderma lucidum transcription factor GLHB-1 for regulating and controlling transcriptional activity of ganoderic acid synthetic genes LSS and SQS as well as coding gene and application thereof

    CN119504964A

  • Ganoderma lucidum transcription factor and application and method thereof in regulating and controlling transcriptional activity of ganoderic acid synthetic gene SQS

    CN120060283A